2021 American Transplant Congress
A Comparison of Belatacept Conversion Regimens from Calcineurin Inhibitor-Based Immunosuppression
Cedars-Sinai Medical Center, Los Angeles, CA
*Purpose: Outcomes with varying belatacept conversion protocols from calcineurin inhibitor (CNI)-based immunosuppression have been published but no standard protocol has been established. Beginning in 2012,…2021 American Transplant Congress
Renal Preservation with Belatacept-Based versus Everolimus-Based Immunosuppression in Lung Transplant Recipients
*Purpose: Renal dysfunction is one of the most common long-term complications among lung transplant recipients (LTRs). Calcineurin-inhibitor (CNI) nephrotoxicity is a recognized contributor to renal…2021 American Transplant Congress
Tolerability of De Novo and Conversion Belatacept Regimens in Kidney Transplantation
*Purpose: Belatacept, a selective T lymphocyte co-stimulation blocker, has been shown to be a safe and effective maintenance therapy for immunosuppression. We investigated the long-term…2021 American Transplant Congress
TIGIT Agonism Improves Immunosuppression of Cd8 T Cells by Ctla-4ig in a Treg Dependent Manner
Emory University Transplant Center, Emory University, Atlanta, GA
*Purpose: Costimulation blockade therapeutics for immunosuppression in transplant are less toxic than calcineurin inhibitors offering improved graft longevity and patient quality of life, but belatacept-resistant…2021 American Transplant Congress
Association of Belatacept Conversion on Patient and Allograft Survival in Kidney Transplant Recipients with Congestive Heart Failure
Department of Medicine, University of Wisconsin-Madison, Madison, WI
*Purpose: Calcineurin inhibitors (CNI) exert deleterious effect on cardiovascular risk in kidney transplant recipients (KTRs). Belatacept conversion may reduce CV risk in KTRs. We hypothesized…2021 American Transplant Congress
Belatacept Exposure Not Associated With Rejection. Can Doses be Lowered without Compromising Efficacy?
*Purpose: Phase 1 and 2 belatacept(BELA) pharmacokinetic(PK) studies informed dosing in phase 3 studies. PK data from these studies revealed higher BELA troughs on Day…2021 American Transplant Congress
Obesity Impacts Acute Rejection but Not Allograft Function Improvement in the Setting of Belatacept Conversion
University of Illinois at Chicago, Chicago, IL
*Purpose: There is limited data regarding belatacept conversion in obese patients as an alternative to calcineurin inhibitor (CNI) immunosuppression. Pharmacokinetic (PK) data suggests increasing clearance…2021 American Transplant Congress
P40 Homodimers Induce Il-15 to Promote Endogenous Donor-reactive Memory Cd8 T Cell Activation within High-risk Cardiac Allografts
Inflammation and Immunity, Cleveland Clinic, Cleveland, OH
*Purpose: Longer cold ischemic storage (CIS) time prior to transplant results in increased proliferation of endogenous donor-reactive memory CD8 T cells within complete MHC-mismatched cardiac…2021 American Transplant Congress
Kidney Transplant Outcomes Stratified by Race with a Calcineurin and Steroid Free Regimen
Pharmacy, Duke University Medical Center, Durham, NC
*Purpose: This study aimed to describe the outcomes, stratified by race, associated with belatacept and sirolimus immunosuppression after alemtuzumab induction.*Methods: This was a retrospective, single-center…2021 American Transplant Congress
Immunosuppression Reduction Strategies for Polyoma BK Viremia in Kidney Transplant Patients on Belatacept-Based Immunosuppression
*Purpose: The mainstay of treatment for BK infection is immunosuppression (IS) reduction, however limited literature provides guidance for treatment of patients with a belatacept-based IS…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 30
- Next Page »